Neurosterix advances NTX-253, an oral M4 PAM, into phase 2 for schizophrenia after phase 1 shows promising safety and pharmacokinetics.
|Slideshows|February 3, 2020
- Vol 37, Issue 1
- Volume 37
- Issue 1
In This Issue of Psychiatric Times: Vol 37, No 1
Author(s)Laurie Martin
13 psychiatry stories you may have missed: A round-up of the latest issue of Psychiatric Times, all in one place, with a bonus PDF.
Advertisement
Articles in this issue
over 6 years ago
Celebrating Progress, but Challenges Remainover 6 years ago
Autoimmune Encephalitis: What Psychiatrists Need to Knowover 6 years ago
The Opening of the Maudsley Hospital: January 31, 1923over 6 years ago
Disaster Response, Mental Health, and Community Resilienceover 6 years ago
Psychiatrists Are Not the Retiring KindAdvertisement
Related to this article
Andrew A. Nierenberg, MD, explains how a learning health network helps clinicians measure outcomes and redesign bipolar disorder care together with patients.
Routine symptom measures sharpen psychiatric diagnosis, speed remission, flag relapse risk, and turn EHR data into a learning system for better care.
Seaport begins phase 2a trial of GlyphAgo for generalized anxiety disorder with sleep disturbance, testing liver-sparing agomelatine dosing and tracking sleep, anxiety outcomes.
FDA clears Motivista, a prescription smartphone digital therapeutic, to reduce negative symptoms of schizophrenia—supported by phase 3 results and strong patient engagement.
Vortioxetine eases depression in older adults, while cognitive gains stay mixed—showing selective boosts in attention and processing speed, not consistent global improvement.
A remitted patient with ARFID faces panic after a crash, showing why recovery includes somatic fear, not just eating behavior.
Lisa Harding, MD, urges psychiatrists to gather histories, deprescribe safely, and send focused sleep referrals now that orexin agonists have arrived for narcolepsy.
Advertisement
Advertisement
Trending on Psychiatric Times
1
FDA Grants Clearance to Motivista, the First Authorized Treatment for Negative Symptoms of Schizophrenia
2
Muscarinic Treatment for Schizophrenia: A Presynaptic Answer to a Presynaptic Problem
3
How a Learning Health Network Could Transform Bipolar Disorder Treatment: A Conversation With Andrew Nierenberg, MD
4
First Patient Dosed in Phase 2a Trial of GlyphAgo for Generalized Anxiety Disorder and Sleep Disturbance
5